Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence.
paper
Cited
Public
- Authors
- Kranzler, Henry R; Gelernter, Joel; Anton, Raymond F; Arias, Albert J; Herman, Aryeh; Zhao, Hongyu; Burian, Linda; Covault, Jonathan
- Year
- 2009
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 19320626
- DOI
- 10.1111/j.1530-0277.2009.00913.x
- PMCID
- PMC2772659
BACKGROUND: Glutamate neurotransmission plays an important role in a variety of alcohol-related phenomena, including alcohol self-administration by both animals and humans. Because the risk for alcohol dependence (AD) is genetically influenced, genes encoding glutamate receptors are candidates to contribute to the risk for AD. We examined the role of variation in the 3' region of GRIK1, the gene that encodes the GluR5 receptor subunit of the kainic acid glutamate receptor, on risk for AD. We focused specifically on this gene because topiramate, a glutamate modulator that binds to the GluR5 subunit, has shown robust efficacy in the treatment of AD. METHODS: We genotyped 7 single nucleotide polymorphisms (SNPs) in the 3'-half of GRIK1, which includes 3 differentially spliced exons, in a sample of EA control subjects (n = 507) and subjects with AD (n = 1,057). RESULTS: We found nominally significant evidence of association to AD for 3 SNPs (rs2832407 in intron 9, rs2186305 in intron 17, and rs2832387 in the 3'UTR). Empirical p-value estimation revealed that only rs2832407 was significantly associated to phenotype (p = 0.043). DISCUSSION: These findings provide support for the hypothesis that variation in the 3' portion of the gene encoding the GluR5 kainate receptor subunit contributes to the risk for AD. Further research is needed to ascertain whether this SNP is itself functional or whether the association reflects linkage disequilibrium with functional variation elsewhere in the gene and whether this SNP moderates topiramate's effects in the treatment of AD.
No figures extracted from this document.
1β20 of 25
Next β
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Association between GRIK1 rs363598 and intergenic rs360932 variants and susceptibility to autism spectrum disorders in Egyptian children. | Bassiony H et al. | β | 2025 | β |
| FYN Tyrosine Kinase Gene Polymorphisms in Alcohol-Dependent Korean Patients. | Huh SY et al. | β | 2025 | β |
| GRIK1 genotype and effect of topiramate for alcohol use: a systematic review. | Kotake K et al. | β | 2025 | β |
| Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate. | Kranzler HR et al. | β | 2025 | β |
| An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial. | Votaw VR et al. | β | 2023 | β |
| Antagonism of GluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal. | Quijano CardΓ© NA et al. | β | 2021 | β |
| Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. | Kranzler HR et al. | β | 2021 | β |
| Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. | Kranzler HR et al. | β | 2021 | β |
| World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. | Hartwell EE et al. | β | 2021 | β |
| Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes. | Regier PS et al. | β | 2020 | β |
| Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures. | Lieberman R et al. | β | 2020 | β |
| Pharmacogenetics of drug dependence: Polymorphisms of genes involved in glutamate neurotransmission. | Nudmamud-Thanoi S et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction. | Giacometti LL et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. | Manhapra A et al. | β | 2019 | β |
| A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. | Schuckit MA | β | 2018 | β |
| A Whole Methylome Study of Ethanol Exposure in Brain and Blood: An Exploration of the Utility of Peripheral Blood as Proxy Tissue for Brain in Alcohol Methylation Studies. | Clark SL et al. | β | 2018 | β |
| Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). | Morley KC et al. | β | 2018 | β |
| Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats. | Van Nest D et al. | β | 2017 | β |
| GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose-Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers. | Yang BZ et al. | β | 2017 | β |
| Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. | Soyka M et al. | β | 2017 | β |
| A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. | Li QS et al. | β | 2016 | β |
| Association study of DRD2 A2/A1, DRD3 Ser9Gly, DΞ²H -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence. | Ragia G et al. | β | 2016 | β |
| Ethanol-Associated Changes in Glutamate Reward Neurocircuitry: A Minireview of Clinical and Preclinical Genetic Findings. | Bell RL et al. | β | 2016 | β |
| Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry. | Levran O et al. | β | 2016 | β |
| Overview of the Genetics of Alcohol Use Disorder. | Tawa EA et al. | β | 2016 | β |
| Possible involvement of the circadian pathway in alcohol use disorder in a South African adolescent cohort. | Dalvie S et al. | β | 2016 | β |
| Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. | Seneviratne C et al. | β | 2015 | β |
| Alcohol Dependence Genetics: Lessons Learned From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses. | Hart AB et al. | β | 2015 | β |
| Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. | Hammond CJ et al. | β | 2015 | β |
| Gene-gene interaction of ΞΌ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. | Misailidis G et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| The effects of single nucleotide polymorphisms in glutamatergic neurotransmission genes on neural response to alcohol cues and craving. | Bach P et al. | β | 2015 | β |
| The pharmacogenetics of alcohol use disorder. | Jones JD et al. | β | 2015 | β |
| Association of single-nucleotide polymorphisms in a metabotropic glutamate receptor GRM3 gene subunit to alcohol-dependent male subjects. | Xia Y et al. | β | 2014 | β |
| Expression of glutamatergic genes in healthy humans across 16 brain regions; altered expression in the hippocampus after chronic exposure to alcohol or cocaine. | Enoch MA et al. | β | 2014 | β |
| Expression of specific ionotropic glutamate and GABA-A receptor subunits is decreased in central amygdala of alcoholics. | Jin Z et al. | β | 2014 | β |
| Genetic variants of glutamate receptor gene family in Taiwanese Kawasaki disease children with coronary artery aneurysms. | Lin YJ et al. | β | 2014 | β |
| GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate. | Kranzler HR et al. | β | 2014 | β |
| GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink. | Kranzler HR et al. | β | 2014 | β |
| Pharmacotherapy of alcohol use disorders: seventy-five years of progress. | Zindel LR et al. | β | 2014 | β |
| Posttreatment effects of topiramate treatment for heavy drinking. | Kranzler HR et al. | β | 2014 | β |
| Selective increases of AMPA, NMDA, and kainate receptor subunit mRNAs in the hippocampus and orbitofrontal cortex but not in prefrontal cortex of human alcoholics. | Jin Z et al. | β | 2014 | β |
| Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine? | Leggio L et al. | β | 2014 | β |
| Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism. | Kranzler HR et al. | β | 2014 | β |
| Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. | Kranzler HR et al. | β | 2014 | β |
| Pharmacogenetically driven treatments for alcoholism: are we there yet? | Arias AJ et al. | β | 2012 | β |
| Human variation in alcohol response is influenced by variation in neuronal signaling genes. | Joslyn G et al. | β | 2010 | β |
| Pharmacogenetics of alcohol and alcohol dependence treatment. | Kranzler HR et al. | β | 2010 | β |
| Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. | MartΓnez C et al. | β | 2010 | β |
| [Comorbidity of substance use disorders and attention-deficit hyperactivity disorders: pathogenesis and therapy]. | Fallgatter AJ et al. | β | 2009 | β |